Roy T. Steigbigel

7.7k citations

75 papers · 4.6k indexed · 1 hit paper · h-index 36

Co-authors: Richard D. Pearson Stanley W. Chapman Jack Fuhrer Lucille K. Georg C. J. K. Wang Libero Ajello Marie C. Gelato Margaret A. McNurlan
Topics: HIV Research and Treatment (24 papers)HIV/AIDS drug development and treatment (19 papers)HIV-related health complications and treatments (11 papers)
Cited by: Virology Infectious Diseases Emergency Medicine
Journals: New England Journal of Medicine Proceedings of the National Academy of Sciences Journal of Clinical Investigation
Partner nations: United States Germany Australia

In The Last Decade

Roy T. Steigbigel

74 papers receiving 4.3k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Method of reliable determination of minimal lethal antibiotic concentrations

1980 414 citations Richard D. Pearson, Roy T. Steigbigel et al. Antimicrobial Agents and Chemotherapy profile →

Peers

Countries citing papers authored by Roy T. Steigbigel

Since Specialization

Citations

This map shows the geographic impact of Roy T. Steigbigel's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Roy T. Steigbigel with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Roy T. Steigbigel more than expected).

Fields of papers citing papers by Roy T. Steigbigel

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Roy T. Steigbigel. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Roy T. Steigbigel. The network helps show where Roy T. Steigbigel may publish in the future.

Co-authorship network of co-authors of Roy T. Steigbigel

This figure shows the co-authorship network connecting the top 25 collaborators of Roy T. Steigbigel. A scholar is included among the top collaborators of Roy T. Steigbigel based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Roy T. Steigbigel. Roy T. Steigbigel is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Efficacy and safety of raltegravir for treatment of HIV for 5 years in the BENCHMRK studies: final results of two randomised, placebo-controlled trials 2013 ·The Lancet Infectious Diseases ·Joseph J. Eron,David A. Cooper,Roy T. Steigbigel,Bonaventura Clotet,José M. Gatell,Princy Kumar,Jürgen K. Rockstroh,Mauro Schechter,Martin Markowitz,Patrick Yéni,Mona Loutfy,Adriano Lazzarin,Jeffrey L. Lennox,Kim M. Strohmaier,Hong Wan,Richard J. O. Barnard,Bach-Yen Nguyen,Hedy Teppler	96
2	A Phase II Study of DAS181, a Novel Host Directed Antiviral for the Treatment of Influenza Infection 2012 ·The Journal of Infectious Diseases ·Richard B. Moss,(unknown),Robert Sanders,S B Hawley,(unknown),Roy T. Steigbigel	109
3	Nef Inhibits Glucose Uptake in Adipocytes and Contributes to Insulin Resistance in Human Immunodeficiency Virus Type I Infection 2011 ·The Journal of Infectious Diseases ·(unknown),June Chunqiu Hou,(unknown),Jeffrey E. Pessin,Roy T. Steigbigel	18
4	Targeting pandemic influenza: a primer on influenza antivirals and drug resistance 2010 ·Journal of Antimicrobial Chemotherapy ·Ronald B. Moss,Richard T. Davey,Roy T. Steigbigel,Fang Fang	55
5	Antiretroviral Activity, Pharmacokinetics, and Tolerability of MK-0518, a Novel Inhibitor of HIV-1 Integrase, Dosed As Monotherapy for 10 Days in Treatment-Naive HIV-1-Infected Individuals 2006 ·JAIDS Journal of Acquired Immune Deficiency Syndromes ·Martin Markowitz,Javier O Morales-Ramirez,Bach‐Yen Nguyen,Colin Kovacs,Roy T. Steigbigel,David A. Cooper,(unknown),Robert A. Schwartz,Robin Isaacs,Lucinda R. Gilde,Larissa Wenning,Jing Zhao,Hedy Teppler	293
6	Long-Term Efficacy, Safety, and Tolerability of Indinavir-Based Therapy in Protease Inhibitor--Naive Adults with Advanced HIV Infection 2003 ·Clinical Infectious Diseases ·Martin Hirsch,Roy T. Steigbigel,S Staszewski,Deborah K. McMahon,Margaret A. Fischl,Bernard Hirschel,K. Squires,Mark J. DiNubile,Charlotte M. Harvey,Jianping Chen,Randi Y. Leavitt,(unknown)	13
7	Antigen Burden Is a Major Determinant of Human Immunodeficiency Virus–Specific CD8⁺T Cell Maturation State: Potential Implications for Therapeutic Immunization 2003 ·The Journal of Infectious Diseases ·Lynda Tussey,(unknown),(unknown),Bradley H. Edwards,(unknown),Karen M. Grimm,Joseph G. Joyce,Rupert Vessey,Roy T. Steigbigel,Michael Robertson,John W. Shiver,Paul A. Goepfert	52
8	Improved Insulin Sensitivity and Body Fat Distribution in HIV-Infected Patients Treated With Rosiglitazone: A Pilot Study 2002 ·JAIDS Journal of Acquired Immune Deficiency Syndromes ·Marie C. Gelato,Dennis C. Mynarcik,(unknown),Roy T. Steigbigel,Jack Fuhrer,Collin Brathwaite,(unknown),Mark R. Wax,Margaret A. McNurlan	96
9	Association of Severe Insulin Resistance With Both Loss of Limb Fat and Elevated Serum Tumor Necrosis Factor Receptor Levels in HIV Lipodystrophy 2000 ·JAIDS Journal of Acquired Immune Deficiency Syndromes ·Dennis C. Mynarcik,Margaret A. McNurlan,Roy T. Steigbigel,Jack Fuhrer,Marie C. Gelato	188
10	A Randomized, Controlled Trial of Indinavir, Zidovudine, and Lamivudine in Adults with Advanced Human Immunodeficiency Virus Type 1 Infection and Prior Antiretroviral Therapy 1999 ·The Journal of Infectious Diseases ·Martin Hirsch,Roy T. Steigbigel,S Staszewski,John W. Mellors,Ernesto G. Scerpella,Bernard Hirschel,Joep M. A. Lange,Kathleen Squires,(unknown),Anne R. Meibohm,Randi Y. Leavitt,(unknown)	86
11	Insulin-like Growth Factor System in Patients With HIV Infection: Effect of Exogenous Growth Hormone Administration 1999 ·Journal of Acquired Immune Deficiency Syndromes & Human Retrovirology ·Dennis C. Mynarcik,Robert A. Frost,Charles H. Lang,(unknown),Margaret A. McNurlan,Peter J. Garlick,Roy T. Steigbigel,Jack Fuhrer,(unknown),Marie C. Gelato	19
12	Anti-F(ab′) ₂ Antibody in HIV Type 1 Infection: Relationship to Hypergammaglobulinemia and to Antibody Specific to the V3 Loop Region of Glycoprotein 120 1998 ·AIDS Research and Human Retroviruses ·(unknown),S.K. Pearson,Roy T. Steigbigel	2
13	Responsiveness of muscle protein synthesis to growth hormone administration in HIV-infected individuals declines with severity of disease. 1997 ·Journal of Clinical Investigation ·M.A. McNurlan,P.J. Garlick,Roy T. Steigbigel,(unknown),R A Frost,Charles H. Lang,Robert W. Johnson,(unknown),(unknown),Jack Fuhrer,(unknown)	61
14	Wasting in the acquired immune deficiency syndrome is associated with multiple defects in the serum insulin‐like growth factor system 1996 ·Clinical Endocrinology ·Robert A. Frost,Jack Fuhrer,Roy T. Steigbigel,Peter Mariuz,Charles H. Lang,Marie C. Gelato	79
15	Impairment of Phagosome-Lysosome Fusion in HIV-1-Infected Macrophages 1996 ·Journal of Acquired Immune Deficiency Syndromes & Human Retrovirology ·(unknown),Barbara P. Craddock,(unknown),Roy T. Steigbigel	9
16	Poly A-linked colorimetric microtiter plate assay for HIV reverse transcriptase 1993 ·Journal of Virological Methods ·Kazuo Suzuki,Barbara P. Craddock,(unknown),(unknown),Roy T. Steigbigel	85
17	Chemiluminescent Enzyme-Linked Immunoassay for Reverse Transcriptase, Illustrated by Detection of HIV Reverse Transcriptase 1993 ·Analytical Biochemistry ·Kazuo Suzuki,Barbara P. Craddock,(unknown),Roy T. Steigbigel	10
18	A Solid-Phase Enzyme Immunoassay (Gonozyme®) Test for Direct Detection of Neisseria gonorrhoeae Antigen in Urogenital Specimens from Patients at a Sexually Transmitted Disease Clinic 1985 ·Sexually Transmitted Diseases ·(unknown),(unknown),Marilyn A. Menegus,Roy T. Steigbigel	4
19	Method of reliable determination of minimal lethal antibiotic concentrationsbreakdown → 1980 ·Antimicrobial Agents and Chemotherapy ·Richard D. Pearson,Roy T. Steigbigel,(unknown),Stanley W. Chapman	414
20	A Case of Phaeohyphomycosis Caused by a New Species of Phialophora 1974 ·Mycologia ·Libero Ajello,Lucille K. Georg,Roy T. Steigbigel,C. J. K. Wang	246

About Roy T. Steigbigel

Roy T. Steigbigel is a scholar working on Virology, Infectious Diseases and Emergency Medicine, having authored 75 papers that have together received 4.6k indexed citations. Recurring topics across this work include HIV Research and Treatment (24 papers), HIV/AIDS drug development and treatment (19 papers) and HIV-related health complications and treatments (11 papers). The work is most often cited by research in Virology (1.1k citations), Infectious Diseases (2.2k citations) and Emergency Medicine (573 citations). Roy T. Steigbigel has collaborated with scholars based in United States, Germany and Australia. Frequent co-authors include Richard D. Pearson, Stanley W. Chapman, Jack Fuhrer, Lucille K. Georg, C. J. K. Wang, Libero Ajello, Marie C. Gelato, Margaret A. McNurlan, Norbert J. Roberts and Dennis C. Mynarcik. Their work appears in journals such as New England Journal of Medicine, Proceedings of the National Academy of Sciences and Journal of Clinical Investigation.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact